7th ICHNO Abstract book

7th ICHNO 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ page 95

Conclusion POC assay performed well for discriminating OSCC. Additional studies are underway to further confirm these results and compare with a lab-based ELISA test. PO-180 Infiltrating CD8+ T-cells and PD-L1 expression as indicators for immunotherapy in sinonasal cancer F. López 1 , R. García-Marín 1 , L. Suárez-Fernández 1 , V. Naves-Cabal 1 , C. Riobello 1 , S. Reda 1 , M. Hermsen 1 , J.L. Llorente 1 1 Hospital Universitario Central de Asturias. Instituto de Investigación Sanitaria del Principado de Asturias, Department of Otolaryngology, Oviedo, Spain Purpose or Objective Sinonasal squamous cell carcinoma (SNSCC) patients have a poor survival rate and treatment options are limited. Our aim was to identify patients that may benefit from therapy with immune checkpoint inhibitors. Material and Methods Four tissue microarray blocks were constructed including triplicate cilinders of 57 SNSCC. Each block also contained normal mucosa samples as controls. The presence of CD8+ lymphocytes and tumoural PD-L1 expression were evaluated by immunohistochemistry. The stainings were evaluated by 2 independent observers and results were correlated to clinico-pathological characteristics and follow-up data. Results High level presence of CD8+ lymphocytes in the tumour compartment occurred in 11/57 (19%), low level in 39/57 (69%) and absence in 6/57 (11%) cases. 2-year disease- specific survival (DFS) was 0%, 34% and 71% in high level, low level and absence of CD8 cells, respectively (p=0.006). PD-L1 expression was observed in 23/57 (40%) of cases and did not correlate with clinico-pathological parameters or DFS. Tumours with CD8+/PD-L1+ and CD8+/PD-L1- expression had a significant worse DFS than CD8-/PD-L1+ and CD8-/PD-L1- cases (p=0.015). Conclusion Our data showed that SNSCC are immunogenic tumours with up to 89% of cases harbouring some level of intratumoural CD8+ lymphocyte infiltrate. The presence of CD8+ cells was correlated to worse survival, as has been observed previously in other tumour types. We also found 40% of tumours to express PD-L1. Together these results indicate that SNSCC patients could benefit from immunotherapy releasing the PD-1/PD-L1 immune checkpoint and reactivating the already present cytotoxic CD8+ lymphocytes to exercise their antitumor activity. Pembrolizumab and nivolumab have already received FDA approval for clinical application in recurrent or metastatic HNSCC and may also be considered for treatment of recurrent sinonasal SCC. PO-181 Immunotherapy in Advanced Head and Neck Squamous Cell Cancer. Retrospective evaluation in Argentina A. Falco 1 , M. Angel 2 , J.F. Perez 3 , F. Cayol 4 , I. Pucella 4 , G. Gomez Abuin 5 , J. Florez 5 , E. Adelchanow 6 , J. Palazzo 7 , F. Palazzo 8 , J.M. Carrera 9 , D. Pereira 10 , R. Giglio 9 1 Instituto Alexander Fleming, Medical Oncology, Ciudad Automoma de Buenos Aires, Argentina; 2 Instittuto Fleming, Medical Oncology, Buenos Aires, Argentina; 3 Instituto Fleming, Medical Oncology, Buenos Aires, Argentina; 4 Hospital Italiano de Buenos Aires, Medical Oncology, Buenos Aires, Argentina; 5 Hospital Aleman de Buenos Aires, Medical Oncology, Buenos Aires,

Argentina; 6 Hospital Posadas, Medical Oncology, Buenos Aires, Argentina; 7 Centro de Atención Integral del Paciente Oncológico, Radiation Oncologist, San Miguel de Tucuman, Argentina; 8 Centro de Atención Integral del Paciente Oncológico, Medical Oncology, San Miguel de Tucuman, Argentina; 9 Instituto Angel Roffo, Medical Oncology, Buenos Aires, Argentina; 10 Instituto Angel Roffo, Radiation Oncologist, Buenos Aires, Argentina Purpose or Objective Introduction: The standard of care in first line treatment for advanced Head and Neck Squamous Cell Carcinoma (SCCHN) includes polychemotherapy based on platinum and Cetuximab. In recent years, and with results from 2 phase III studies, immunotherapy (antiPD1/PDL1) has proved to be effective and with a manageable toxicity profile in patients (pts) progressed to platinum. Objectives:To describe the clinical-pathological characteristics, efficacy (overall survival -OS-, objective response rates -ORR- and progression free survival -PFS-) and toxicity of pts with advanced SCCHN treated with immunotherapy. Material and Methods Retrospective multinstitutional descriptive analysis of patient treated with immunotherapy for advanced SCCHN from 03/2017 to 05/2018, in Argentinian academic centers (Hospital Alemán, HIBA, Instituto Ángel Roffo, Hospital Posadas, IAF, CAIPO). Treatment setting were defined as Platinum refractory (progression within 6 months after multimodal therapy using platinum regimen); first and subsequent lines for metastatic disease. Statistix 8.0 was used for statistical analysis. Results Forty (N) pts with were included with a median (md) age of 63.8 years (r: 36-84), 28 (70 %) male, 90 % exposure to tobacco, 17% HPV positive. Location: Oropharynx 35% (n = 14) Oral cavity 30% (n = 12), larynx / hypopharynx 35% (n = 14). Performance status (PS) 0-1: 72%, 2: 22%. Immunotherapy indication: Platinum refractory: n = 12 (30%), 2°line n = 21 (52%), 3° line n = 7 (17%). Treatment: Nivolumab 18 pts (45%), Pembrolizumab 20 (50%), Durvalumab 2 (5%). Previous Cetuximab use: 17 pts (42%). Toxicity: Grade 1-2: 70% (n 28) and Grade 3-4: 12.5% (n 5) . ORR: complete responses: 7.7% partial responses: 25.6%, md PFS: 13.9 months (95% CI: 9.5-23.4), md OS 22.9 months (95% CI .14.8-NA). Conclusion The results of this study are shown in agreement with what is evidenced in the literature, with a higher proportion of patients with fewer previous treatment lines. In spite of the weakness for being a retrospective analysis, it highlights the multi-institutional cooperation, relevant for the study of this pathology. PO-182 Prognostic impact of hematological profile in oropharyngeal cancer treated with chemoradiotherapy G. Fanetti 1 , D.P. Rojas 2 , G. Marvaso 2 , D. Alterio 2 , S. Gandini 3 , A. Ferrari 2 , C. Gobitti 1 , E. Palazzari 1 , F. Navarria 1 , E. Coassin 1 , A. De Paoli 1 , M. Cossu Rocca 4 , F. Nolé 4 , E. Vaccher 5 , M. Ansarin 6 , V. Lupato 7 , C. Furlan 8 , D. Ciardo 2 , R. Orecchia 9 , G. Franchin 1 , B.A. Jereczek-Fossa 2 1 IRCCS Centro di Riferimento Oncologico CRO National Cancer Institute, Division of Radiation Oncology, Aviano, Italy; 2 IRCCS European Institute of Oncology, Division of Radiation Oncology, Milano, Italy; 3 IRCCS European Institute of Oncology, Division of Epidemiology and Biostatistics, Milano, Italy ; 4 IRCCS European Institute of Oncology, Division of Medical Oncology of Urogenital and